Mumbai: Cipla, an Indian multinational pharmaceutical company, has announced that the United States Food and Drugs ...

Mumbai: Pharma major, Cipla, has received final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (‘NDA’) submitted for ‘Nilotinib Capsules 50, ...

IST, the barometer index, the S&P BSE Sensex, declined 461.33 points or 0.61% to 75,274.63. The Nifty 50 index slipped 139.85 points or 0.63% to 22,768.05.

Cipla announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the new drug application (NDA) submitted for 'Nilotinib Capsules 50, 150 and 200 mg' ...

In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib ...

Stocks like CIE Automotive India, Sanofi Consumer Healthcare, Delta Corp, Mahindra and Mahindra, Grindwell Norton, Keystone ...

The NSE Nifty 50 closed 19.75 points or 0.09% lower at 22,913.15, while the BSE Sensex ended 203.22 points or 0.27% down at ...

Nilotinib is an FDA approved drug used for the treatment of Philadelphia Chromosome Positive CML, which is a cancer of blood ...

Cipla has received final US FDA approval for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia ...

mAbs were purchased from several companies. A full list of the mAbs utilized is provided in Table 1. All the mAbs were mouse-anti human, with the exception of ROR-γt mAb, Phospho-Stat3 ...